Merck Animal Health has announced the approval by the United States Department of Agriculture (USDA) of Nobivac NXT Canine Flu H3N2, a new vaccine to protect dogs against canine influenza H3N2.

This vaccine, using a 'revolutionary' RNA particle technology, will be available in veterinary clinics across the country at the end of this summer, the laboratory assures.

It is the first and only canine flu vaccine based on this technology, offering optimized protection while guaranteeing comfort and safety.

The vaccine is intended for healthy dogs aged eight weeks or older, Merck emphasizes.

Copyright (c) 2024 CercleFinance.com. All rights reserved.